Member Info for B2HS2L

RNS 30 July : 'The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox'

Doesn't sound like Tap will only answer questions. He will want to aid understanding of the info in the poster at least.

30 Jul 2025 07:00

RNS Number : 1598T

Avacta Group PLC

30 July 2025

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

LONDON AND PHILADELPHIA - July 30, 2025 - Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment.

The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.

+++

RNS 15 September 2025

Notice of Interim Results and Investor Presentation

Change of Date, Time and Location of ESMO Abstract Presentation

ESMO Congress Update

The Company confirms that the date, time and location of the abstract being presented at the European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, has changed. The updated details are included below:

Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

+++

* No mention of phase 1a in todays RNS

* Larger venue booked

* Tap speaks for 45 mins, not the original 15 mins.

I think the poster content is for phase 1a and 1b.

Can't leave the audience waiting for phase 1b when 1a is all that will be provided. - That was the subject of the original presentation.

...and a much bigger hall?

CC discusses here:

https://avacta.wistia.com/medias/eeb61opgzb

08:00 - R&D Spotlight Episode 10

RNS 19 June 2025

Avacta Group plc

New Response in the FAP-Dox (AVA6000) Phase 1b Trial

LONDON and PHILADELPHIA - June 19, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces a new partial response observed in a patient with salivary gland cancer (SGC) in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b trial.

This further signal of antitumor activity in this disease setting is encouraging as the expansion cohort continues to enroll in the indication of salivary gland cancer. This patient is a 69-year-old male with metastatic salivary gland cancer. His prior therapy includes surgery and radiation with no prior systemic therapy. His combined tumor diameter was reduced at the first scan by almost 50%, qualifying as a partial response.

++++

Important to note that he has no prior Doxorubicin treatment.

An unconfirmed partial response occurred on 19.06.2025 ( > 12 weeks ago).

We hope to be advised soon of a confirmed partial response, when the patient's combined tumor diameter is checked on the next scan.

Whether that news will be RNS'd if the check is satisfactory is unknown, but I don't see why not if success is to be celebrated by all parties.

Another 'efficacy' reminder to BP, FDA /MHRA etc would be ideal with this AVA6000 trial still in phase 1.

IF...you ever

"put this one in a drawer with don’t open till 2025",

it's likely you found it by mistake searching for super strength haemorrhoid cream.

Recommend staying off the booze.

D-WynThornCool

Why c**p on this board - nobody is liking these posts.

📢 Take it to Smiths / Wood / dump it somewhere else 📢

54retiresoon - a great post thanks.

I posted this recently -

TNBC phase 1b results not expected until early 2026, but BP in the data room will see results as they arrive.

'We believe the critical data for partnering is evidence that FAP-Dox (AVA6000) has the expected clinical effect in breast cancer' -

a quote from a Trinity Delta report.

Assuming that is still the case, and BP think a good TNBC phase1b result will trigger a partnering RNS.

AVA6103 Ph 1 scheduled to start Q126.

Post announcement, I would expect the situation to trigger a buyout via FOMO from a few BP.

It's not what I want, but I feel a partnering statement will provoke a buyout.

...photo of lots of people looking at the poster >>5 deep!

RNS 30.07.25 -

'the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025.'

Phil Banks asked - Would a partial response have to be announced via RNS when it occurs, or can that information be reserved for the conference?

I would say that a partial response during phase 1b in SGC, TNBC or STS could also be announced in Berlin.

RNS 19.06.25

Avacta announces a new partial response observed in a patient with salivary gland cancer (SGC) in the dose expansion phase

of the FAP-Dox (AVA6000) Phase 1b trial. (the second PR observed)

+++

Avacta wants all followers of the SGC trial to know FAP-Dox is capable of delivering partial responses to AVA6000 therapy.

If / when there are more PR's in SGC, then we would expect to be so advised.

Likewise it is in the gift of the company to advise a PR event in TNBC, but I would agree the impact of such news would best be delivered at conference by William Tap in October, particularly if there has been > 1 PR event.

Every BP with access to the data room will already know what the TNBC trial results so far are long before Berlin in October anyway.

Https://www.insights.bio/

Publishers of BIOCONJUGATION INSIGHTS

"The essential resource supporting translation and commercialization Peer-reviewed, Open Access Publications"

Your content marketing partner for life sciences

*Roundtables and Webinars

*Present a webinar or roundtable with us:

*Generate qualified leads

*Demonstrate your company’s expertise and capabilities

*Stimulate discussion around a topic of significant importance

*Educate individuals on crucial regulatory, scientific or technical issues

*Make a noise around a new product or service offering launch

Get in touch to see how we can partner with you

+++

Perhaps Avacta already is a partner.

..or as a relative saw it, a 2:1 in pottery, and five years debt.

Never been near a kiln since.

I want to know what level of service is being contracted, and are AVACTA getting what they paid for.

Shareholders find the present service level totally inadequate, so any payment to ICR is a waste of company funds.

Vinegrad gone, - it's time for further service improvement. - sufficient for you?

What we don't know is the extent of the shareholder comms services contracted from ICR by Avacta.

ie

Are ICR providing the 'cut and paste' response to shareholder questions, that is all that Avacta have specified?

Higher levels of service would cost more.

For me that's a possibility.

Avacta are surely aware shareholders often get no response to their questions.

I hope Karen Harrison has been tasked with improving shareholder interaction.

ICRhealthcare are unfit for purpose and taking money under false pretences, - the contract should be ripped up.

Karen Harrison already seen to be a smoother operator than Vinegrad. 🎆

VS

Yulii hired because

'There’s an incredible amount of interest in AVA6103, or FAP-EXd as we now call it, although the company’s strategy at this point is to protect this asset until we have sight of the initial human data, such is its value.'

Simon on a 70 hr week and CC concerned, so she hired someone she has hired before.

Bella - I don't understand why she is still an NED if she leads R&D and is CEO, unless it's for bookmarking purposes.

I was not responding to whether she was in it for the long term.

However, as you've brought it up, she is commuting between US and UK regularly, and obviously loves being a mom.

She probably doesn't want to commute long term, would anyone?

In CC's position, I would prefer the commuting to end, and would back any move that took Avacta to America.

She's biding her time in that respect.

I think she is just bookmarking a spare Avacta NED directorship.

She is still head of R&D, and is Avacta's CEO.

So why does CC / the company need this NED?

CC to resign NED and immediately re-assign to AN Other as circumstances dictate?